A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.

doi:10.1097/JTO.0b013e31824fe9e6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2012

Cuffe Sinead, Bourredjem Abderrahmane, Graziano Stephen, Pignon Jean-Pierre, Domerg Caroline, Ezzalfani Monia, Seymour Lesley, Strevel Elizabeth, Burkes Ronald, Capelletti Marzia, Jänne Pasi A, Tsao Ming-Sound, Shepherd Frances A

Abstract excerpt

INTRODUCTION: The staging of node-negative non-small-cell lung cancer is modified in the 7th edition TNM classification. Here, we pool data from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial and the Cancer and Leukemia Group B-9633 trial to explore the prognostic and predictive effects of the new T-size descriptors and KRAS mutation status. METHODS: Node-negative patients were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA, Neoplasm

Share to Neoplasm Staging

Share to Platinum Compounds

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 22588152
DOI: 10.1097/JTO.0b013e31824fe9e6
PMCID: PMC3638870

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.PMID 22588152Read ↗

Combined assessment of<i>KRAS</i>mutational status and tumor size has no impact on prognosis in early-stage non-small cell lung cancerSemantic proximity Read ↗

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.Semantic proximity Read ↗

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsSemantic proximity Read ↗

The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.Semantic proximity Read ↗

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma.Semantic proximity Read ↗

KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.Semantic proximity Read ↗

Current readings: Window-of-opportunity trials for thoracic malignancies.Semantic proximity Read ↗

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.Semantic proximity Read ↗

Equalizing prognostic disparities in stage III KRAS-mutant NSCLC: addition of durvalumab to combined chemoradiotherapy improves survivalSemantic proximity Read ↗

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.Semantic proximity Read ↗

Optimal Adjuvant Therapy in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer Harboring EGFR Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.